Hofseth Biocare ASA: Proxy Rights at Annual General Meeting

Roger Hofseth, Chairman of the Board of Hofseth BioCare ASA, has in connection to the upcoming Annual General Meeting on 26 May 2016, received proxy rights from shareholders representing 42 905 157 shares in the company, equal to 35.11 per cent of the voting rights.
 
Roger Hofseth owns as per the registration date for the AGM a total of 24 831 109 shares, equal to 20.32 per cent of the outstanding shares in the company. 20 981 109 shares is owned via his fully owned company, Roger Hofseth AS, and 3 850 000 shares via a forward contract.
 
After the receipt of the above-mentioned proxies, Mr. Hofseth represents a total of 63 886 266 shares, equal to 52.28 per cent of the voting rights at the Annual General meeting in Hofseth BioCare ASA.
 
For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
 
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. Hofseth BioCare's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
 
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.